Bloemenkamp, K. W., et al. “Risk of Venous Thrombosis with Use of Current Low-Dose Oral Contraceptives Is Not Explained by Diagnostic Suspicion and Referral Bias”. Archives of Internal Medicine 159, no. 1 (1999): 65–70.

Bultman, S. J. “Emerging Roles of the Microbiome in Cancer”. Carcinogenesis 35, no. 2 (2014): 249–55.

Bushnell, C. D. “Stroke in Women: Risk and Prevention Throughout the Lifespan”. Neurologic Clinics 26, no. 4 (2008): 1161-xi.

Cauci, S., et al. “Effects of Third-Generation Oral Contraceptives on High-Sensitivity C-Reactive Protein and Homocysteine in Young Women”. Obstetrics and Gynecology 111, no. 4 (2008): 857–64.

Centers for Disease Control. “Long – Term Oral Contraceptive Use and the Risk of Breast Cancer. The Centers for Disease Control Cancer and Steroid Hormone Study”. JAMA 249, no. 12 (1983): 1591–95.

Chasan-Taber, L., et al. “Epidemiology of Oral Contraceptives and Cardiovascular Disease”. Annals of Internal Medicine 128, no. 6 (1998): 467–77.

Chen, L., et al. “Mechanisms Linking Inflammation to Insulin Resistance”. International Journal of Endocrinology (2015): 508409.

Cummings, S. R., et al. “Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk”. Journal of the National Cancer Institute 101, no. 6 (2009): 384–98.

De Bastos, M., et al. “Combined Oral Contraceptives: Venous Thrombosis”. Cochrane Database of Systematic Reviews 3, no. 3 (2014): CD010813.

De Bruijn, S. F., et al. “Case-Control Study of Risk of Cerebral Sinus Thrombosis in Oral Contraceptive Users and in [Correction of Who Are] Carriers of Hereditary Prothrombotic Conditions. The Cerebral Venous Sinus Thrombosis Study Group”. British Medical Journal 316, no. 7131 (1998): 589–92.

Diab, K. M., et al. “Contraception in Diabetic Women: Comparative Metabolic Study of Norplant, Depot Medroxyprogesterone Acetate, Low Dose Oral Contraceptive Pill and CuT380A”. Journal of Obstetrics and Gynaecology Research 26, no. 1 (2000): 17–26.

Dinger, J. C., et al. “The Safety of a Drospirenone-Containing Oral Contraceptive: Final Results from the European Active Surveillance Study on Oral Contraceptives Based on 142,475 Women – Years of Observation”. Contraception 75, no. 5 (2007): 344–54.

Duarte, C., et al. “Oral Contraceptives and Systemic Lupus Erythematosus: What Should We Advise to Our Patients?” Acta Reumatológica Portuguesa 35, no. 2 (2010): 133–40. European Medicines Agency. “PhVWP Monthly Report on Safety Concerns, Guidelines, and General Matters”. No. 1201 (January 2012). http://www.ema.europa.eu/docs/en_GB /document_library/Report/2012/01/WC500121387.pdf.